IL-17 is implicated in the pathogenesis
BRIEF DEFINITIVE REPORT
Rheumatoid arthritis (RA) is a chronic autoimmune disease in which proinfl ammatory cytokines, such as TNF ␣ , IL-6, and IL-1, play dominant pathological roles. More recently, IL-17 has been suggested to play an important additional role in the induction and maintenance of RA ( 1, 2 ) . Thus, IL-17 is present in the synovium of RA patients and contributes to the production of IL-6 and MMP-1 in the joint ( 2, 3 ) , whereas treatment of human macrophages with IL-17 in vitro stimulates the production of TNF ␣ and IL-1 ␤ ( 4 ). IL-17 can also synergize with TNF ␣ to induce cytokine and chemokine production by synovial fi broblasts and cartilage destruction in vitro and can promote osteoclastogenesis ( 1, 5, 6 ) .
IL-17 is a proinfl ammatory cytokine produced predominantly by T helper cells (Th17 cells) and, although there is controversy over the signals required for the diff erentiation of murine and human Th17 cells, both murine and human CD4 + Th17 T cells require IL-23 for their proliferation and maintenance ( 7 ) . IL-23 is a heterodimeric protein composed of a p19 subunit and a p40 subunit, whereas IL-12, an important cytokine for Th1 cell diff erentiation, is formed when the p40 subunit dimerizes with p35 ( 8 ) .
The role of TNF ␣ in RA is well documented, with TNF ␣ -blocking biologics causing amelioration of clinical symptoms (e.g., pain, joint swelling, and stiff ness), laboratory parameters of infl ammation (e.g., CRP and ESR), and radiological progression of disease ( 9, 10 ) . Although TNF ␣ plays a direct pathological role in RA, its contribution to disease pathogenesis is amplifi ed by its ability to promote the expression is responsible for delivering the inhibitory signal, Th1/Th17 responses were assessed in p55 Ϫ / Ϫ , p75 Ϫ / Ϫ , and WT mice immunized 14 d previously with type II collagen in CFA. This time point was chosen because maximal T cell responses are normally detected around this time.
The results show conclusively that inhibition of Th1/Th17 responses occurs via the p55 and not the p75 TNF receptor. Thus, the production of IL-17 and IFN ␥ was dramatically higher in collagen or anti-CD3 mAb -stimulated LN cell cultures from p55 Ϫ / Ϫ mice compared with either WT or p75 Ϫ / Ϫ mice ( Fig. 2 A ) . Further analysis by fl ow cytometry confi rmed of other proinfl ammatory cytokines. For example, TNF ␣ has been shown in vitro to drive the production of IL-17 by equipping DC with the ability to diff erentiate T cells toward a Th17 phenotype ( 11 ) . On this basis, it would be predicted that TNF ␣ blockade would result in reduced IL-17 expression, and to test this hypothesis in vivo, we investigated the dependence of IL-17 expression on TNF ␣ in collagen-induced arthritis (CIA) . Surprisingly, our data show that TNF ␣ is an important negative regulator, not only of IL-17 but also of IFN ␥ production by T cells. We propose that this forms a part of a negative feedback loop that attempts to limit the intensity and/or duration of Th17 and Th1 responses.
RESULTS AND DISCUSSION
To investigate the eff ect of blockade of TNF ␣ on the production of IL-17, DBA/1 mice were immunized with bovine type II collagen in CFA. After onset of arthritis, mice were treated with soluble TNFR-Fc for 10 d and the production of IL-17 and IFN ␥ by LN cells was determined by ELISA. Signifi cantly increased IL-17 and IFN ␥ production was observed after stimulation of LN cells from TNFR-Fc -treated mice with collagen or anti-CD3 mAb in vitro, and a trend toward enhanced production of these cytokines was observed even in unstimulated LN cells ( Fig. 1 ) . As expected, arthritis severity was signifi cantly reduced in TNFR-Fc -treated mice despite the increased IL-17 and IFN ␥ production ( Fig. 1 ) .
We next set out to establish whether the increased IFN ␥ and IL-17 production in vitro by LN cells after blockade of TNF ␣ was paralleled by increased numbers of Th1 and Th17 cells in vivo. In addition, we compared the eff ect of TNF ␣ blockade on numbers of Th1/Th17 cells during the T cell expansion phase (days 0 -14 after immunization) versus the phase of T cell contraction (days 1 -14 after disease onset). For this experiment, we used anti-TNF ␣ mAb (TN3-19.12), which has been characterized extensively in CIA ( 12 ) . Anti-TNF ␣ mAb treatment lead to a signifi cant expansion of the proportion of CD4 + IFN ␥ + cells in inguinal LN, irrespective of whether it was administered from days 0 -14 after immunization or days 1 -14 after disease onset (Fig. S1 , available at http://www.jem .org/cgi/content/full/jem.20072707/DC1). There was a trend toward increased numbers of CD4 + IL-17 + cells during the expansion phase and a signifi cant increase in CD4 + IL-17 + cells during the contraction phase.
It was concluded that early TNF ␣ blockade led to a signifi cant expansion of Th1 cells, whereas late TNF ␣ blockade led to a signifi cant expansion of both Th1 and Th17 cells. The coordinate expansion of both Th17 and Th1 cells in vivo after blockade of TNF ␣ is surprising and challenges the assumption that the diff erentiation of these two subsets is mutually antagonistic ( 13, 14 ) . Less than 0.2% of CD4 + cells from control or anti-TNF ␣ -treated mice were double positive for IFN ␥ and IL-17 ( Fig. S1 ).
Thus far, the data suggest that signaling via the TNF receptor inhibits Th1/Th17 responses. To confi rm this fi nding, and to establish which of the two TNF receptors (p55 or p75) 
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strongly Th1/Th17-skewing properties of CFA. The fact that expanded populations of Th1 and/or Th17 cells were observed in inguinal LN of p55 Ϫ / Ϫ and anti-TNF -treated mice before the onset of arthritis indicates that there was not simply a redistribution of cells away from the joint to the LN.
We next sought to identify the mechanism by which TNF ␣ reduces Th17 and Th1 cell activity. IL-12 and IL-23 share a common subunit, p40. Dimerization of p40 with p35 forms IL-12, which is involved in the diff erentiation of Th1 cells, whereas dimerization of p40 with p19 forms IL-23, which has an important role in the generation and/or survival of Th17 cells. Hence, one possible explanation for our fi ndings is that TNF ␣ conditions myeloid cells toward reduced p40 expression, and we set out to address this question using thioglycolate-elicited macrophages stimulated with LPS in vitro. Pretreatment of macrophages before LPS stimulation with 30 or 100 ng/ml of TNF ␣ produced a dosedependent reduction of p40 upon subsequent stimulation with LPS ( Fig. 3 ) . The maximum inhibition of p40 production by LPS-stimulated macrophages was ‫ف‬ 50%, and the failure to obtain greater suppression was attributed to the fact that LPS alone would inevitably produce signifi cant quantities of TNF ␣ . TNF ␣ pretreatment also suppressed IL-6 production at 100 ng/ml, but not at 30 ng/ml, but had no eff ect on IL-1 ␤ production at either dose ( Fig. 3 ) . This shows that the eff ect of TNF ␣ on cytokine production was selective and did not cause global suppression of cellular activity.
that the proportion of CD4 + T cells producing IL-17 and IFN ␥ in the LN of p55 Ϫ / Ϫ mice was signifi cantly greater than in those from WT or p75 Ϫ / Ϫ mice ( Fig. 2 B ) . However, increased IFN ␥ and IL-17 responses were not observed in anti-CD3 -stimulated LN cells from nonimmunized p55 Ϫ / Ϫ mice ( Fig. 2,  A and B ) , indicating that the T cells were not skewed toward Th1/Th17 responses before immunization. The percentage of CD4 + cells in immunized WT mice coexpressing IFN ␥ and IL-17 was low ( ‫ف‬ 0.1%) and was not altered in p55 Ϫ / Ϫ or p75 Ϫ / Ϫ mice.
Despite the increase in Th1/Th17 responses observed in immunized p55 Ϫ / Ϫ mice, the proliferative responses of T cells from p55 Ϫ / Ϫ , p75 Ϫ / Ϫ , and WT mice did not vary signifi cantly in response to collagen or anti-CD3 mAb stimulation ( Fig. 2 C ) , and the percentages of CD4 + T cells in the LN of WT and p55 Ϫ / Ϫ mice were comparable, although slightly reduced in p75 Ϫ / Ϫ mice ( Fig. 2 C ) . The percentage of regulatory CD4 + Foxp3 + T cells remained unchanged in the p55 Ϫ / Ϫ and p75 Ϫ / Ϫ mice when compared with WT mice. IL-4 and IL-5 were undetectable in immunized WT, p55 Ϫ / Ϫ , and p75 Ϫ / Ϫ mice, which was attributed to the antibodies, the pathogenic potential of these T cells is eff ectively neutralized.
One of the mechanisms by which anti-TNF ␣ therapy is known to act in human RA is by preventing infl ammatory cell infi ltration into the joint ( 16 ) . On this basis, we hypothesized that the mechanism by which TNF ␣ blockade is able to reduce disease activity while expanding populations of Th1 and Th17 cells is by preventing the migration of T cells into the joint. To validate this hypothesis, arthritic DBA/1 mice were treated for 10 -14 d with anti-TNF ␣ mAb or control Ab. The mice were then killed and cells harvested from paws and inguinal LN for subsequent analysis by fl ow cytometry.
Anti-TNF ␣ treatment of established arthritis reduced total numbers of CD4 + IFN ␥ + and CD4 + IL-17 + cells in joints Next, we addressed the question of whether p40 expression was elevated in vivo in the absence of signaling via the p55 TNFR. To quantify p40 expression without any form of manipulation in vitro, mRNA was extracted from LN cells immediately postmortem and analyzed by real-time PCR. LN cells from immunized p55 Ϫ / Ϫ mice were found to express sixfold greater levels of p40 mRNA compared with immunized WT and p75 Ϫ / Ϫ mice ( Fig. 3 ) . This confi rms the ability of TNF ␣ to suppress p40 expression in vivo.
We then questioned whether inhibition of IL-12/IL-23 p40 activity in p55 Ϫ / Ϫ mice would result in a reduction of IFN ␥ /IL-17 production and reduced numbers of Th1/Th17 cells. Treatment with a blocking anti -mouse p40 mAb in p55 Ϫ / Ϫ mice from the day of immunization to day 14 after immunization partially or completely abrogated both the increase in IL-17 and IFN ␥ production and the expansion of CD4 + IL-17 + and CD4 + IFN ␥ + cells ( Fig. 4 ) . These fi ndings strongly suggest that at least one of the mechanisms by which TNF ␣ infl uences the development and/or survival of Th1 and Th17 cells is by inhibition of IL-12/IL-23 p40 expression, although other mechanisms may also be involved.
These fi ndings raise the important question of why TNF ␣ blockade is eff ective in reducing disease activity despite increasing numbers of Th1 and Th17 cells. To address this question, we used an adoptive transfer system established previously ( 15 ) to confi rm that the expanded Th1/Th17 cells were potentially pathogenic. Spleen and LN cells from arthritic mice treated for 10 -14 d with anti-TNF ␣ mAb or control Ab were pooled and injected into CB-17 SCID mice (5 × 10 7 cells/mouse or 10 7 cells/mouse). The SCID recipients were also injected i.p. with 100 μ g of type II collagen without adjuvant, which is required for the successful transfer of arthritis ( 15 ) . The proportion of LN cells to spleen cells was ‫ف‬ 1:10 and was identical in both anti-TNF ␣ -treated and control groups.
Transfer of 5 × 10 7 cells from either anti-TNF ␣ -treated or control mice led to effi cient transfer of arthritis, although onset of arthritis was much earlier when donor cells were derived from anti-TNF ␣ -treated mice (Fig. S2 , available at http://www.jem.org/cgi/content/full/jem.20072707/DC1). However, when the numbers of donor cells were reduced to 10 7 cells, there was a dramatic diff erence between the two groups, with the cells from the anti-TNF ␣ -treated donors showing vastly superior transfer of arthritis (Fig. S2) . Remarkably, when the recipient SCID mice were treated with anti-TNF ␣ mAb from the time of cell transfer, the development of arthritis was largely abrogated (Fig. S2) . This experiment shows conclusively that anti-TNF ␣ therapy expands the population of pathogenic T cells. However, the pathogenicity of these donor cells is largely blocked by anti-TNF ␣ treatment of the recipients.
The enhanced capacity of lymphoid cells from anti-TNF ␣ -treated mice to adoptively transfer arthritis to SCID mice demonstrates that the expansion of Th1/Th17 cells may have pathological consequences when the anti-TNF ␣ " brake " is removed. However, in the presence of TNF ␣ -neutralizing 
Anti-TNF ␣ therapy is now undergoing evaluation in an increasing number of diseases and its eff ect is not universally benefi cial. For example, TNF ␣ blockade was shown to increase both the rate and frequency of relapse in patients with existing multiple sclerosis ( 23 ). In EAE, TNF ␣ Ϫ / Ϫ mice developed enhanced infl ammation and demyelination, whereas treatment of susceptible mice with TNF ␣ reduced the severity of disease ( 24 ) . In another study, EAE failed to resolve in TNF ␣ Ϫ / Ϫ or TNFR Ϫ / Ϫ mice, suggesting that TNF ␣ plays an important role in resolution of infl ammation ( 25 ) . Similarly, in murine lupus, administration of rTNF ␣ was found to be protective ( 26 ) , whereas TNF ␣ defi ciency was associated with increased production of antinuclear antibodies and accelerated onset of disease ( 27 ) . Hence, an important question is whether the deleterious eff ects of TNF ␣ blockade in these diseases are mediated via the expansion of Th1 and/or Th17 cells.
As discussed in a previous paragraph, TNF ␣ has been reported to decrease p40 expression in human macrophages ( 18 ) . Therefore, the fi ndings presented in this paper may have implications for human RA. As in CIA, the therapeutic effi cacy of TNF ␣ blockade in human RA is indisputable ( 28 ) , but it is possible that the rare occurrence of side eff ects, such as antinuclear autoantibodies and demyelination ( 29 ) , could be explained by an amplifi cation of Th17 and/or Th1 responses. However, it is also possible that the increased Th1/Th17 responses in the periphery versus the joint after anti-TNF ␣ therapy may have benefi cial consequences by increasing resistance to infection. This may help to explain the relatively low impact of TNF ␣ blockade on susceptibility to infection ( 30 ) .
In conclusion, the results of this study show that TNF ␣ plays at least two distinct and opposing roles in CIA. First, it contributes to the accumulation of Th1 and Th17 cells in arthritic joints, and second, it plays an inhibitory role by limiting total numbers of these pathogenic T cell subsets in peripheral lymphoid organs.
MATERIALS AND METHODS
Mice. DBA/1, C57BL/6, and CB-17 SCID mice were purchased from Harlan. p55 Ϫ / Ϫ and p75 Ϫ / Ϫ mice were bred in house on a C57BL/6 background. All experimental procedures were approved by the Ethical Review Process Committee.
Immunization. DBA/1 and C57BL/6 mice were immunized with CFA plus bovine or chicken type II collagen, respectively ( 31 ) . Arthritis severity was assessed as follows: 0, normal; 1, slight swelling and/or erythema; 2, pronounced edematous swelling; and 3, ankylosis. Each limb was graded, giving a maximum score of 12.
Anticytokine therapy. Blockade of TNF ␣ was achieved using murine p75 TNFR-Fc (donated by GlaxoSmithKline) or hamster anti -mouse TNF ␣ mAb (TN3-19.12; provided by R.D. Schreiber, Washington University School of Medicine, St. Louis, MO). Blockade of IL-12/IL-23 was achieved using rat anti -mouse p40 mAb (c17.8; donated by G. Trinchieri, then at Wistar Institute, Philadelphia, PA). LN cell culture. LN cells were cultured at a density of 2 × 10 6 cells/ml in RPMI-1640 with l-glutamine plus 10% FCS, penicillin/streptomycin, sodium pyruvate, and ␤ 2 -mercaptoethanol and stimulated with 50 μ g/ml by 63% and 67%, respectively, despite being present in increased numbers in inguinal LN ( Fig. 5 ) . It was concluded that one of the mechanisms of action of anti-TNF ␣ therapy is to inhibit immigration of pathogenic T cells to the joint or prevent their emigration from LN. It was beyond the scope of the present study to investigate the mechanisms by which anti-TNF ␣ prevents T cell accumulation in the joint, but they are likely to include reduced chemokine and adhesion molecule expression in the joint, as has been proposed for human RA ( 16, 17 ) .
The key fi nding to emerge from this study is that, in addition to its proinfl ammatory role, TNF ␣ is also responsible for dampening down Th1 and Th17 responses within the context of autoimmune arthritis. We propose that this represents a negative feedback mechanism that normally serves to limit the duration of T cell -driven infl ammatory responses.
There are several published studies that support the fi ndings reported here. For example, as observed in the present study, it was reported that TNF ␣ selectively inhibits p40 expression in human and mouse myeloid cells in an IL-10 -independent manner ( 18, 19 ) . In CIA, it was shown that there was elevated IFN ␥ production (IL-17 was not measured) and increased numbers of CD4 + T cells in TNF Ϫ / Ϫ mice compared with WT mice ( 20 ) . More recently, it was shown that i.p. administration of rTNF ␣ reduced IFN ␥ production as well as the clinical severity of adjuvant-induced arthritis in rats ( 21 ) , which is also consistent with our fi ndings. In experimental autoimmune encephalomyelitis (EAE), it was reported that there was enhanced IL-12/IL-23 p40 expression in p55 Ϫ / Ϫ mice and increased Th1 (but not Th17) cells in the CNS compared with WT mice ( 22 ) . 
